@article{582dcfe0a39d4e4f9ceee8f8c840cbb0,
title = "Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions",
abstract = "The development of pancreatic cancer requires the acquisition of oncogenic KRas mutations and upregulation of growth factor signaling, but the relationship between these is not well established. Here, we show that mutant KRas alters mitochondrial metabolism in pancreatic acinar cells, resulting in increased generation of mitochondrial reactive oxygen species (mROS). Mitochondrial ROS then drives the dedifferentiation of acinar cells to a duct-like progenitor phenotype and progression to PanIN. This is mediated via the ROS-receptive kinase protein kinase D1 and the transcription factors NF-κB1 and NF-κB2, which upregulate expression of the epidermal growth factor, its ligands, and their sheddase ADAM17. In vivo, interception of KRas-mediated generation of mROS reduced the formation of pre-neoplastic lesions. Hence, our data provide insight into how oncogenic KRas interacts with growth factor signaling to induce the formation of pancreatic cancer.",
keywords = "Growth factor signaling, Kras, Mitochondria, Oxidative stress, PanIN, Pancreatic cancer",
author = "Liou, {Geou Yarh} and Heike D{\"o}ppler and DelGiorno, {Kathleen E.} and Lizhi Zhang and Michael Leitges and Crawford, {Howard C.} and Murphy, {Michael P.} and Peter Storz",
note = "Funding Information: This work was supported by NIH grants CA200572, CA140182 (to P.S.), and CA159222 (to H.C.C.) and by grant 197261 from the Norwegian Research Council (to M.L.). We thank the Pancreatic Cancer Action Network (PanCAN) for their support. M.P.M. holds patents in the area of mitochondria-targeted antioxidants and is a consultant for Antipodean Pharmaceuticals, which is developing MitoQ as a potential pharmaceutical. Funding Information: This work was supported by NIH grants CA200572, CA140182 (to P.S.), and CA159222 (to H.C.C.) and by grant 197261 from the Norwegian Research Council (to M.L.). We thank the Pancreatic Cancer Action Network (PanCAN) for their support. M.P.M. holds patents in the area of mitochondria-targeted antioxidants and is a consultant for Antipodean Pharmaceuticals, which is developing MitoQ as a potential pharmaceutical. Publisher Copyright: {\textcopyright} 2016 The Authors.",
year = "2016",
month = mar,
day = "15",
doi = "10.1016/j.celrep.2016.02.029",
language = "English (US)",
volume = "14",
pages = "2325--2336",
journal = "Cell reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "10",
}